Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT

Ann Thorac Surg. 2007 May;83(5):1865-7. doi: 10.1016/j.athoracsur.2006.11.051.

Abstract

A patient with myocardial failure after repair of an acute type A aortic dissection had acute heparin-induced thrombocytopenia develop during extracorporeal membrane oxygenation. Heparin was discontinued and the anticoagulant was switched to the direct thrombin inhibitor bivalirudin given with a bolus of 0.5 mg/kg followed by a continuous infusion of 0.5 mg/kg/h. Using this protocol, activated clotting time values ranged from 200 to 220 seconds. After prolonged extracorporeal membrane oxygenation support and recovery of left ventricular function, a right ventricular assist device was implanted during extracorporeal membrane oxygenation support with bivalirudin anticoagulation. For this procedure an additional bolus of 0.25 mg/kg bivalirudin was given, and the infusion rate increased to 1 mg/kg/h to achieve activated clotting time values of 300 to 350 seconds. Surgery was successfully performed with moderate intraoperative and postoperative blood loss and transfusion requirements.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticoagulants / therapeutic use*
  • Aortic Aneurysm / surgery
  • Aortic Dissection / surgery
  • Cardiac Surgical Procedures / adverse effects
  • Extracorporeal Membrane Oxygenation*
  • Female
  • Heart Failure* / etiology
  • Heart Failure* / surgery
  • Heart-Assist Devices
  • Heparin / adverse effects*
  • Hirudins
  • Humans
  • Peptide Fragments / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Thrombocytopenia / chemically induced*

Substances

  • Anticoagulants
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • Heparin
  • bivalirudin